The National Academy of Sciences and the National Academy of Medicine launched this initiative in 2015 to inform decision-making related to recent advances in human genome-editing research. The ...
BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd. (Nasdaq: GMDA), a leading cellular and immune therapeutics company, today announced an agreement with Editas Medicine, Inc., a leading genome editing company, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results